Navidence

Based in the US, Navidence offers data-driven solutions to navigate the health data landscape, empowering healthcare stakeholders with actionable evidence through advanced analytics and study design capabilities. Navidence, founded in 2022 and headquartered in Aurora, US, specializes in providing data analytics solutions for the healthcare industry. The company has made one notable deal to date, with its most recent deal occurring on January 27, 2026. The founder's history is not detailed within the available information.

Navidence specializes in providing a comprehensive platform designed to navigate the evolving health data landscape through data definitions that facilitate the conversion of data into actionable evidence. The core offerings of the Navidence platform include sophisticated study design capabilities paired with advanced data science techniques, enabling clients to execute real-world data (RWD) and real-world evidence (RWE) studies effectively. These services cater to various stakeholders in the healthcare sector, including pharmaceutical companies, contract research organizations, and healthcare providers, primarily focusing on markets across North America and Europe. By employing robust methodologies and technological innovations, Navidence aims to streamline processes associated with clinical research, thereby enhancing decision-making and outcomes in patient care.

Navidence generates revenue primarily through B2B transactions, engaging directly with pharmaceutical and healthcare organizations that require robust data analysis and evidence generation services. The company's revenue structure consists of subscription-based models for accessing its platform and services, alongside potential partnerships for tailored research projects. Clients may enter into agreements that encompass a range of study designs and data analytic services, with pricing plans reflecting the complexity and scope of the projects undertaken. The flagship products associated with the Navidence platform provide critical insights that inform drug development and market strategies, positioning the company as a vital resource in the health data analytics landscape.

In January 2026, Navidence raised an undisclosed amount of SEED funding co-led by new investors Grand Ventures and Nina Capital. The company will use the funding to enhance its tools and services that improve real-world data usability in clinical research. Navidence is focusing on expanding its offerings in the healthcare sector and aims to explore additional geographic markets in North America and Europe by leveraging its advanced data analytics capabilities.